Key result
Telmisartan suppressed pathological remodeling and myocardial fibrosis in rats with myocardial infarction via PPAR-γ agonistic activities, independent of its antihypertensive effects.
Why the study?
Does telmisartan suppress pathological remodeling after myocardial ischemia in a rat model?
Does telmisartan suppress pathological remodeling after myocardial ischemia in a rat model?
Telmisartan suppresses pathological remodeling after myocardial infarction through PPAR-γ agonistic activities, independent of its blood pressure-lowering effects.
No takes yet. Share an insight, caveat, or question.
Telmisartan may attenuate post-MI remodeling via PPAR-γ in rats; leaves open translation to human therapy pending clinical trials.
Nagashima et al. (2012) studied Myocardial infarction (n=26). Telmisartan vs. Saline control was evaluated on Pathological remodeling (end-diastolic left ventricular diameter, ventricular septum thickness, myocardial fibrosis). Telmisartan suppressed pathological remodeling and myocardial fibrosis in rats with myocardial infarction via PPAR-γ agonistic activities, independent of its antihypertensive effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: